Finally big drugmakers are taking notice, culminating with Pfizer Inc.’s $5.4 billion acquisition of one of the more promising drugs to treat sickle cell disease. The drug giant’s purchase of Inc. is … https://www.bloomberg.com/news/articles/2022-08-18/pfizer-pfe-global-blood-gbt-tie-up-shows-new-focus-on-sickle-cell-disease